小柯机器人

他汀类药物或可用于治疗肠道菌群失调
2020-05-10 21:40
来源：小柯机器人

比利时鲁汶大学Jeroen Raes、法国索邦大学Karine Clément等研究人员合作发现，他汀类药物或可用于治疗肠道菌群失调。相关论文于2020年5月6日在线发表于国际学术期刊《自然》。

据研究人员介绍，微生物组分类研究最近确定了拟杆菌2（Bact2）肠型，这是一种与系统性炎症相关的肠道菌群结构，在人的稀便中有很高的患病率。Bact2的特征是高比例的拟杆菌、低比例的费氏杆菌和低微生物细胞密度，其患病率从一般人群中的13％到炎症性肠病患者中的78％不等。据报道，在肥胖和代谢合并症的发展过程中，粪便稠度和炎症状态的变化使研究人员提出，这些发展可能与不良微生物Bact2肠型存在相关性。
 
通过队列（n=888）定量粪便代谢组中的肥胖相关微生物群改变，研究人员将他汀类药物确定为微生物组多样化的关键协变量。通过关注未接受他汀类药物治疗的人群，研究人员发现Bact2的患病率与体重指数相关，从瘦或超重参与者的3.90％增加到肥胖参与者的17.73％。Bact2型个体的系统性炎症水平高于根据其肥胖状况预测的水平，这表明Bact2是不良微生物群。
 
研究人员还观察到，与肥胖相关的微生物群失调与他汀类药物治疗呈负相关，从而导致他汀类药物治疗的肥胖参与者的Bact2患病率较低，为5.88％。MetaCardis心血管疾病数据集（n=282）和独立的Flemish肠道菌群项目人群（n=2345）均证实了这一发现。在这种情况下，他汀类药物的潜在益处将需要在一项前瞻性临床试验中进行进一步评估，以确定这种作用是否可在随机人群中重现，以及是否可将其用作微生物群调节治疗剂。
 
附：英文原文

Title: Statin therapy is associated with lower prevalence of gut microbiota dysbiosis

Author: Sara Vieira-Silva, Gwen Falony, Eugeni Belda, Trine Nielsen, Judith Aron-Wisnewsky, Rima Chakaroun, Sofia K. Forslund, Karen Assmann, Mireia Valles-Colomer, Thi Thuy Duyen Nguyen, Sebastian Proost, Edi Prifti, Valentina Tremaroli, Nicolas Pons, Emmanuelle Le Chatelier, Fabrizio Andreelli, Jean-Phillippe Bastard, Luis Pedro Coelho, Nathalie Galleron, Tue H. Hansen, Jean-Sbastien Hulot, Christian Lewinter, Helle K. Pedersen, Benoit Quinquis, Christine Rouault, Hugo Roume, Joe-Elie Salem, Nadja B. Sndertoft, Sothea Touch, Marc-Emmanuel Dumas, Stanislav Dusko Ehrlich, Pilar Galan, Jens P. Gtze, Torben Hansen, Jens J. Holst, Lars Kber, Ivica Letunic, Jens Nielsen, Jean-Michel Oppert, Michael Stumvoll, Henrik Vestergaard, Jean-Daniel Zucker, Peer Bork, Oluf Pedersen, Fredrik Bckhed, Karine Clment, Jeroen Raes

Issue&Volume: 2020-05-06

Abstract: Microbiome community typing analyses have recently identified the Bacteroides2 (Bact2) enterotype, an intestinal microbiota configuration that is associated with systemic inflammation and has a high prevalence in loose stools in humans1,2. Bact2 is characterized by a high proportion of Bacteroides, a low proportion of Faecalibacterium and low microbial cell densities1,2, and its prevalence varies from 13% in a general population cohort to as high as 78% in patients with inflammatory bowel disease2. Reported changes in stool consistency3 and inflammation status4 during the progression towards obesity and metabolic comorbidities led us to propose that these developments might similarly correlate with an increased prevalence of the potentially dysbiotic Bact2 enterotype. Here, by exploring obesity-associated microbiota alterations in the quantitative faecal metagenomes of the cross-sectional MetaCardis Body Mass Index Spectrum cohort (n = 888), we identify statin therapy as a key covariate of microbiome diversification. By focusing on a subcohort of participants that are not medicated with statins, we find that the prevalence of Bact2 correlates with body mass index, increasing from 3.90% in lean or overweight participants to 17.73% in obese participants. Systemic inflammation levels in Bact2-enterotyped individuals are higher than predicted on the basis of their obesity status, indicative of Bact2 as a dysbiotic microbiome constellation. We also observe that obesity-associated microbiota dysbiosis is negatively associated with statin treatment, resulting in a lower Bact2 prevalence of 5.88% in statin-medicated obese participants. This finding is validated in both the accompanying MetaCardis cardiovascular disease dataset (n = 282) and the independent  Gut Flora Project population cohort (n = 2,345). The potential benefits of statins in this context will require further evaluation in a prospective clinical trial to ascertain whether the effect is reproducible in a randomized population and before considering their application as microbiota-modulating therapeutics.

DOI: 10.1038/s41586-020-2269-x

Source: https://www.nature.com/articles/s41586-020-2269-x

Nature：《自然》，创刊于1869年。隶属于施普林格·自然出版集团，最新IF：69.504
官方网址：http://www.nature.com/
投稿链接：http://www.nature.com/authors/submit_manuscript.html


本期文章：《自然》：Online/在线发表

分享到:

0